SAN DIEGO, May 17, 2016 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the UBS
2016 Global Health Care Conference in New
York, on Tuesday, May 24 at
2:30 p.m. ET/11:30 a.m. PT. Laurie Stelzer, chief financial officer, will
provide a corporate overview.
The presentation will be webcast through the "Investors" section
of www.halozyme.com, and a recording will be made available for 90
days following the event. To access the live webcast, please visit
Halozyme's website approximately 15 minutes prior to the
presentation to register and download any necessary audio
software.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug PEGPH20,
applies a unique approach to targeting solid tumors, allowing
increased access of co-administered cancer drug therapies to the
tumor in animal models. PEGPH20 is currently in development for
metastatic pancreatic cancer, non-small cell lung cancer, gastric
cancer, metastatic breast cancer and has potential across
additional cancers in combination with different types of cancer
therapies. In addition to its proprietary product portfolio,
Halozyme has established value-driving partnerships with leading
pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme
is headquartered in San Diego. For
more information visit www.halozyme.com.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-the-ubs-2016-global-health-care-conference-300270315.html
SOURCE Halozyme Therapeutics, Inc.